

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/539,543	First Named Inventor: Stefan Berg
Filing Date: June 16, 2005	Attorney Docket No.: 100925-1P US/NS
Examiner: Jeffrey H. Murray	Group Art Unit : 1624
Customer No.: 22466	Confirmation No.: 7996
Title: Novel Compounds Having Selected Inhibiting Effect at GSK3	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir,

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In addition, Applicant(s) wish to call to the Examiner's attention the following commonly-owned, co-pending patent application(s) and patents, and Office Action(s) issued therein:

- 1) U.S. Application Serial No. 10/539,546 U.S. Patent No. \_\_\_\_\_, Attorney Docket No. 100914-1p US, filed on June 16, 2005.
- 2) U.S. Application Serial No. 10/539,545 U.S. Patent No. \_\_\_\_\_, Attorney Docket No. 100915-1P US/NS, filed on June 16, 2005.

### **REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **final Action** or a **Notice of Allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to Deposit Account No. 260166 referencing Attorney Docket No. 100925-1P US
- ☐ (3) after the mailing date of a **final Action** or **Notice of Allowance** but before the payment of the **Issue Fee, AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. \_\_\_\_\_, referencing Attorney Docket No. \_\_\_\_\_, or

### STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that:

- ☐ (1) Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ (2) No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,  
/Kenneth F. Mitchell/

---

Name: Kenneth F. Mitchell  
Dated: November 17, 2008  
Reg. No.: 42,007  
Phone No.: 320-886-7466

Global Intellectual Property, Patents,  
AstraZeneca,  
1800 Concord Pike,  
Wilmington,  
DE-19850-5437